Literature DB >> 7318781

Variation in the baseline sister chromatid exchange frequency in human lymphocytes.

A V Carrano, J L Minkler, D G Stetka, D H Moore.   

Abstract

The utility of the sister chromatid exchange (SCE) assay for human population studies is potentially limited by the variability associated with individual baseline SCE Frequencies. This investigation identifies and quantifies the major sources of preparative and biological variation associated with the determination of baseline SCE frequencies in cultured human lymphocytes. Much of the variation in lymphocyte SCE frequencies is attributable to the amount of bromodeoxyuridine (BrdUrd) available per lymphocyte; the pooled coefficient of variation (CV) over the dose range of 10 to 160 micrometer is about 18%. Other variations in the baseline frequency result from culture-to-culture and slide-to-slide differences. The pooled coefficient of variation among donors is about 10%. The effect of cell-to-cell differences in baseline SCE frequency among donors can be minimized by increasing the number of cells scored per donor. When 20 cells are analyzed per individual the pooled cell-to-cell variation is 9% but when 40 or 80 cells are analyzed it is reduced to 6 and 4% respectively. For a single individual the cell-to-cell coefficient of variation at 100 micrometer BrdUrd is 40.8%. Under our experimental conditions, a 30% increase in SCE frequency between two cohort populations can be detected with a 95% probability at a 5% level of significance when 11 individuals per cohort are studied. For a longitudinal or in vitro dose response study of a single individual, a 50% increase in SCE frequency can be detected with a 95% probability at a 5% level of significance when 25 cells per sample are analyzed. These results indicate the feasibility of applying the SCE bioassay to humans as a measure of environmental stress.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7318781     DOI: 10.1002/em.2860020303

Source DB:  PubMed          Journal:  Environ Mutagen        ISSN: 0192-2521


  9 in total

Review 1.  The risks of handling cytotoxic drugs. I. Methods of testing exposure.

Authors:  G P Kaijser; W J Underberg; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

2.  Variation in spontaneous chromosomal damage as a function of biologic rhythms in women.

Authors:  D D'Souza; I M Thomas; B C Das
Journal:  Hum Genet       Date:  1988-05       Impact factor: 4.132

Review 3.  Sister chromatid exchange (SCE) and structural chromosome aberration in mutagenicity testing.

Authors:  E Gebhart
Journal:  Hum Genet       Date:  1981       Impact factor: 4.132

4.  Sister chromatid exchanges in lymphocytes of petroleum retailers.

Authors:  J W Edwards; B G Priestly
Journal:  Br J Ind Med       Date:  1993-02

5.  Reproducibility of basal and induced DNA single-strand breaks detected by the single-cell gel electrophoresis assay in human peripheral mononuclear leukocytes.

Authors:  O Holz; R Jörres; A Kästner; T Krause; H Magnussen
Journal:  Int Arch Occup Environ Health       Date:  1995       Impact factor: 3.015

6.  Metabolic breakdown of [3H]thymidine and the inability to measure human lymphocyte proliferation by incorporation of radioactivity.

Authors:  J Bodycote; S Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

7.  The distribution of SCEs within and between the genomes of an interspecific hybrid.

Authors:  P Sharp; D Hayman
Journal:  Chromosoma       Date:  1981       Impact factor: 4.316

8.  Ultrasonic induction of sister chromatid exchanges in human lymphocytes.

Authors:  M Haupt; A O Martin; J L Simpson; M A Iqbal; S Elias; A Dyer; R E Sabbagha
Journal:  Hum Genet       Date:  1981       Impact factor: 4.132

9.  Baseline and sodium arsenite-induced sister chromatid exchanges in cultured lymphocytes from patients with Blackfoot disease and healthy persons.

Authors:  W N Wen; T L Lieu; H J Chang; S W Wuu; M L Yau; K Y Jan
Journal:  Hum Genet       Date:  1981       Impact factor: 4.132

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.